

Consolidated Income Statement

YEAR ENDED 30 JUNE 2005

		(As restated)	
	Notes	2005 RMB'000	2004 RMB'000
Turnover	5	2,238,454	1,861,758
Cost of sales		<u>(729,719)</u>	(629,894)
Gross profit		1,508,735	1,231,864
Gain arising from changes in fair value less estimated point-of-sale costs of biological assets	20	175,620	—
Other revenues	6	83,793	30,170
Selling and distribution expenses		(228,090)	(185,094)
General and administrative expenses		(117,420)	(97,555)
Research expenses		(67,763)	(66,709)
Other operating expenses	8	(89,945)	(48,526)
Profit from operations		1,264,930	864,150
Finance costs	9(a)	(75,674)	(10,844)
Share of profits less losses of associates		131,633	64,769
Profit from ordinary activities before taxation	9	1,320,889	918,075
Taxation	10	(10,594)	89,083
Profit from ordinary activities after taxation		1,310,295	1,007,158
Minority interests		708	2,103
Profit attributable to shareholders	11	1,311,003	1,009,261
Earnings per share			
— Basic	12(a)	RMB0.56	RMB0.47
— Diluted	12(b)	RMB0.55	RMB0.46
Dividends			
— Final	13	262,364	181,126
— Special	13	—	17,368
		262,364	198,494

The notes on pages 38 to 79 form an integral part of these financial statements.